0000950170-23-062022.txt : 20231109 0000950170-23-062022.hdr.sgml : 20231109 20231109160641 ACCESSION NUMBER: 0000950170-23-062022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 231392351 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W 8-K 1 xene-20231109.htm 8-K 8-K
false000158231300015823132023-11-092023-11-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2023

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

Canada

001-36687

98-0661854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

200-3650 Gilmore Way

Burnaby, British Columbia, Canada

V5G 4W8

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (604) 484-3300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Shares, without par value

 

XENE

 

The Nasdaq Stock Market LLC
(The Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events

On November 9, 2023, Xenon Pharmaceuticals Inc. (the “Company”) issued a press release announcing that its partner, Neurocrine Biosciences, Inc., reported today that the Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures failed to demonstrate meaningful reduction in seizure frequency. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit Number

Description

99.1

Press Release issued by Xenon Pharmaceuticals Inc. dated November 9, 2023.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 

XENON PHARMACEUTICALS INC.

Date: November 9, 2023

By:

/s/ Sherry Aulin

Sherry Aulin

Chief Financial Officer

 

 

 EX-99.1 2 xene-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

img189401473_0.jpg 

NEWS RELEASE

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency

 

VANCOUVER, British Columbia, November 9, 2023 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced that its partner, Neurocrine Biosciences, Inc., reported today that the Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures (FOS) failed to demonstrate meaningful reduction in seizure frequency. Neurocrine Biosciences guided that no further development with NBI-921352 in FOS is planned at this time.

Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “Although we are disappointed with the outcome of this clinical trial in focal onset seizures, we are grateful to the study participants and investigators, as well as our partner Neurocrine for running this proof-of-concept study. We intend to work closely with Neurocrine to review the data in depth to understand any potential implications for the second ongoing study with NBI-921352 in SCN8A-developmental epileptic encephalopathy. Neurocrine also continues to advance a pre-clinical dual selective Nav1.2/1.6 inhibitor as part of our collaboration.”

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact and include statements regarding the timing of and potential results from clinical trials; and the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of collaborators’ product candidates. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of pandemics, epidemics and other public health crises on our research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, regulatory agencies and related review times, and contractors who act for or on our behalf; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

 

 

 

Investor/Media Contact:

Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

 GRAPHIC 3 img189401473_0.jpg GRAPHIC begin 644 img189401473_0.jpg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end EX-101.PRE 4 xene-20231109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 5 xene-20231109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Entity Address, Country Entity Address, Country Document Type Document Type EX-101.SCH 6 xene-20231109.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity Registrant Name XENON PHARMACEUTICALS INC.
Entity Central Index Key 0001582313
Entity Emerging Growth Company false
Entity File Number 001-36687
Entity Incorporation, State or Country Code Z4
Entity Tax Identification Number 98-0661854
Entity Address, Address Line One 200-3650 Gilmore Way
Entity Address, City or Town Burnaby
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V5G 4W8
City Area Code 604
Local Phone Number 484-3300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, without par value
Trading Symbol XENE
Security Exchange Name NASDAQ
XML 8 xene-20231109_htm.xml IDEA: XBRL DOCUMENT 0001582313 2023-11-09 2023-11-09 false 0001582313 8-K 2023-11-09 XENON PHARMACEUTICALS INC. Z4 001-36687 98-0661854 200-3650 Gilmore Way Burnaby BC CA V5G 4W8 604 484-3300 false false false false Common Shares, without par value XENE NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #3@&E799!YDAD! #/ M P $P @ '&$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 "0 ) #X" 0% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports xene-20231109.htm xene-20231109.xsd xene-20231109_lab.xml xene-20231109_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xene-20231109.htm": { "nsprefix": "xene", "nsuri": "http://www.xenon-pharma.com/20231109", "dts": { "inline": { "local": [ "xene-20231109.htm" ] }, "schema": { "local": [ "xene-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "xene-20231109_lab.xml" ] }, "presentationLink": { "local": [ "xene-20231109_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_65fc7179-eda7-4997-a3cc-040462556778", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "xene-20231109.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65fc7179-eda7-4997-a3cc-040462556778", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "xene-20231109.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "terseLabel": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.xenon-pharma.com/20231109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000950170-23-062022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-062022-xbrl.zip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end